Edition:
United States

TSO3 Inc (TOS.TO)

TOS.TO on Toronto Stock Exchange

2.60CAD
17 Nov 2017
Change (% chg)

$0.03 (+1.17%)
Prev Close
$2.57
Open
$2.56
Day's High
$2.62
Day's Low
$2.55
Volume
46,185
Avg. Vol
175,720
52-wk High
$3.36
52-wk Low
$2.05

Latest Key Developments (Source: Significant Developments)

TSO3 provides duodenoscope regulatory filing update
Thursday, 16 Nov 2017 07:15am EST 

Nov 16 (Reuters) - TSO3 Inc :TSO3 provides duodenoscope regulatory filing update.TSO3-Responded to request for additional information from U.S. FDA; information is in support of submission to extend claims of Sterizone VP4 sterilizer​.  Full Article

TSO3 reports record third quarter 2017 results
Monday, 6 Nov 2017 07:57pm EST 

Nov 6 (Reuters) - TSO3 Inc :TSO3 reports record third quarter 2017 results.TSO3 Inc-qtrly ‍revenue increased to $5.1 million, an 11% sequential increase over $4.6 million recorded in Q2 of 2017​.Qtrly loss per share $0.02‍​.  Full Article

TSO3 provides an update on regulatory activity
Wednesday, 27 Sep 2017 07:00am EDT 

Sept 27 (Reuters) - Tso3 Inc :TSO3 provides an update on regulatory activity.TSO3 Inc - ‍Co has received correspondence from us regulators pertaining to its submission for extended claims for Sterizone VP4 sterilizer​.TSO3 - Regulators asked to clarify some aspects of proposed labeling consistent with reprocessing of specific duodenoscopes using Sterizone VP4 sterilizer​.TSO3 Inc - ‍Regulators asked for specific testing to be documented pertaining to what they describe as "challenge features" of identified devices​.TSO3 Inc - ‍Company is preparing a notice for regulators addressing specific questions, as well as outline intended actions for their comment​.TSO3 Inc - ‍Company's goal is to provide a complete and final response within 180-day limit established by regulators​.  Full Article

TSO3 provides an update on recent activities
Thursday, 7 Sep 2017 04:46pm EDT 

Sept 7 (Reuters) - TSO3 Inc :TSO3 provides an update on recent activities.TSO3 Inc - ‍a hospital in Canada has initiated terminal sterilization of duodenoscopes with company's Sterizone VP4 Sterilizer​.  Full Article

TSO3 files for an extended claim for duodenoscopes
Thursday, 20 Jul 2017 10:45am EDT 

July 20 (Reuters) - TSO3 Inc ::TSO3 files for an extended claim for duodenoscopes.Has filed a 510(k) submission with US regulators for its STERIZONE VP4 Sterilizer.Filing supported by lab data validating STERIZONE VP4 Sterilizer can terminally sterilize multi-channel flexible endoscopes with a duodenovideoscope.  Full Article

TSO3 expands duodenoscope regulatory filing strategy
Wednesday, 14 Jun 2017 09:47am EDT 

June 14 (Reuters) - TSO3 Inc :TSO3 expands duodenoscope regulatory filing strategy.TSO3 Inc says now plans to seek 510(k) clearance for its sterizone VP4 sterilizer from U.S. regulators.Company's goal is to receive us clearance forolympus tjf-Q180V and Pentax ED-3490TK duodenoscopes by end of 2017.TSO3 Inc says seeking clearance for terminal sterilization of two duodenoscopes used in majority of ERCP procedures performed globally.TSO3 Inc- Mark Pasmore, vice president research and development, has resigned due to personal reasons.  Full Article

TSO3 reports Q1 loss per share $0.02
Wednesday, 10 May 2017 06:30am EDT 

May 10 (Reuters) - TSO3 Inc : :TSO3 reports record first quarter 2017 results.TSO3 inc qtrly revenue increased to a record $4.2 million, a 13.5pct sequential increase over $3.7 million recorded in Q4 of 2016.Q1 loss per share $0.02.Q1 earnings per share view $-0.01, revenue view $4.1 million -- Thomson Reuters I/B/E/S.  Full Article

TSO3 qtrly loss per share $0.02
Tuesday, 21 Mar 2017 06:30am EDT 

TSO3 Inc : TSO3 reports record fourth quarter and full year 2016 results . Qtrly revenue increased to $3.75 million compared to $0.15 million in same period last year . TSO3 Inc qtrly loss per share $0.02 . Q4 earnings per share view $-0.01, revenue view $2.8 million -- Thomson Reuters I/B/E/S .TSO3 Inc - "2017 will also see us expand upon use of our existing laboratories in Québec and South Carolina".  Full Article

TSO3 reports Q2 loss per share $0.02
Wednesday, 3 Aug 2016 06:30am EDT 

TSO3 Inc : Q2 loss per share $0.02 .Revenues were $3.0 million in Q2 2016 versus $3.1 million in Q1 2016 and $0.1 million in Q2 2015..  Full Article

TSO3 responds to U.S. FDA on extended claims, gives operations update
Wednesday, 1 Jun 2016 05:00pm EDT 

Tso3 Inc : TSO3 responds to u.s. Regulators on extended claims and provides operations update . Responded to a previously announced request for additional information by U.S. Food and Drug Administration . Co's response allows FDA to continue their review for market clearance on extended claims for sterizone VP4 sterilizer in U.S. . Production and operational improvements co made on assembly facility had a minimal impact on Q2 2016 production . Substantially completed its improvements to its manufacturing facility in Québec .Operational improvements to its assembly facility are designed to increase assembly capacity and efficiency.  Full Article

BRIEF-TSO3 provides duodenoscope regulatory filing update

* TSO3-Responded to request for additional information from U.S. FDA; information is in support of submission to extend claims of Sterizone VP4 sterilizer​ Source text for Eikon: Further company coverage: